Insights into anti-tumor immunity

Area of Science:

• Oncology
• Immunology
• Virology

Background:

• Most cancers have unique mutations, hindering cancer-specific immunity.
• Virus-driven tumors, like Merkel cell carcinoma (MCC), present shared antigens, offering a model to study anti-tumor immunity.
• MCC is driven by Merkel cell polyomavirus (MCPyV) oncoproteins, which are essential for tumor survival and elicit robust T cell responses.

Purpose of the Study:

• To summarize lessons learned from anti-tumor T cell responses in virus-positive MCC.
• To review immune evasion mechanisms in MCC and resistance to immune-based therapies.
• To discuss how novel tools can address open questions in cancer immunotherapy.

Main Methods:

• Utilizing over 20 peptide-MHC class I tetramers to study anti-tumor immunity in MCC patients.
• Analyzing immune evasion strategies in MCC, including MHC downregulation and PD-L1 upregulation.
• Reviewing mechanisms of resistance to PD-1 blockade in MCC and other cancers.

Main Results:

• MCPyV oncoproteins are invariant and immunogenic, driving robust T cell responses in MCC.
• MCC tumors employ immune evasion mechanisms like MHC downregulation and PD-L1 upregulation.
• Approximately 50% of advanced MCC patients do not achieve durable benefit from PD-1 blockade.

Conclusions:

• Investigating MCC provides valuable insights into tumor immunity applicable to cancers without shared antigens.
• Understanding MCC's immune evasion and therapy resistance mechanisms is crucial for improving cancer immunotherapy.
• Developed tools facilitate the study of anti-tumor immunity and can address key questions in the field.